Meeting
2018 Gastrointestinal Cancers Symposium
Second-line chemotherapy in patients with advanced biliary tract cancer.
Authors
Naminatsu Takahara
University of Tokyo, Tokyo, Japan
Naminatsu Takahara , Yousuke Nakai , Hiroyuki Isayama , Takashi Sasaki , Kazunaga Ishigaki , Kei Saito , Suguru Mizuno , Hirofumi Kogure , Minoru Tada , Kazuhiko Koike
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 429)
DOI
10.1200/JCO.2018.36.4_suppl.429
Abstract #
429
Poster Bd #
K22
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim
Poster
2022 ASCO Annual Meeting
Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).
First Author: Arndt Vogel
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113.
First Author: Tatsuya Okuno
Poster
2017 Gastrointestinal Cancers Symposium
Biweekly cisplatin (C) and gemcitabine (G) in patients (pts) with advanced biliary tract cancer (ABTC): A retrospective analysis.
First Author: Daniel H. Ahn